NO964802L - DNA konstruksjoner for effektiv homolog rekombinasjon og anvendelser derav - Google Patents

DNA konstruksjoner for effektiv homolog rekombinasjon og anvendelser derav

Info

Publication number
NO964802L
NO964802L NO964802A NO964802A NO964802L NO 964802 L NO964802 L NO 964802L NO 964802 A NO964802 A NO 964802A NO 964802 A NO964802 A NO 964802A NO 964802 L NO964802 L NO 964802L
Authority
NO
Norway
Prior art keywords
applications
homologous recombination
dna constructs
efficient homologous
efficient
Prior art date
Application number
NO964802A
Other languages
English (en)
Norwegian (no)
Other versions
NO964802D0 (no
Inventor
Douglas A Treco
Michael W Heartlein
Richard F Selden
Original Assignee
Transkaryotic Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22918596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO964802(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Transkaryotic Therapies Inc filed Critical Transkaryotic Therapies Inc
Publication of NO964802D0 publication Critical patent/NO964802D0/no
Publication of NO964802L publication Critical patent/NO964802L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/70—Vector systems having a special element relevant for transcription from fungi
    • C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO964802A 1994-05-13 1996-11-12 DNA konstruksjoner for effektiv homolog rekombinasjon og anvendelser derav NO964802L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/243,391 US5641670A (en) 1991-11-05 1994-05-13 Protein production and protein delivery
PCT/US1995/006045 WO1995031560A1 (en) 1994-05-13 1995-05-11 Dna construct for effecting homologous recombination and uses thereof

Publications (2)

Publication Number Publication Date
NO964802D0 NO964802D0 (no) 1996-11-12
NO964802L true NO964802L (no) 1997-01-09

Family

ID=22918596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964802A NO964802L (no) 1994-05-13 1996-11-12 DNA konstruksjoner for effektiv homolog rekombinasjon og anvendelser derav

Country Status (19)

Country Link
US (1) US5641670A (cs)
EP (1) EP0759082A1 (cs)
JP (1) JPH10500570A (cs)
KR (1) KR100379356B1 (cs)
AU (1) AU709058B2 (cs)
BR (1) BR9507874A (cs)
CA (1) CA2190289A1 (cs)
CZ (1) CZ295115B6 (cs)
FI (1) FI964536A7 (cs)
HU (1) HUT76844A (cs)
IL (1) IL113708A0 (cs)
MX (1) MX9605542A (cs)
NO (1) NO964802L (cs)
NZ (1) NZ285945A (cs)
RU (1) RU2267533C2 (cs)
SK (1) SK146196A3 (cs)
UA (1) UA34493C2 (cs)
WO (1) WO1995031560A1 (cs)
ZA (1) ZA953879B (cs)

Families Citing this family (348)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US6852313B1 (en) 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
HUT62011A (en) * 1989-10-16 1993-03-29 Amgen Inc Process for producing factors influencing the functioning of stem cells
US20040181044A1 (en) * 1989-10-16 2004-09-16 Zsebo Krisztina M. Method of stimulating growth of epithelial cells by administering stem cell factor
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5981730A (en) 1994-04-13 1999-11-09 The General Hospital Corporation RPS gene family, primers, probes, and detection methods
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EP0920508A1 (en) * 1996-08-23 1999-06-09 Chiron Corporation HUMAN POLYHOMEOTIC 1 ($i(hph1)) ACTS AS AN ONCOGENE
NZ506214A (en) 1996-09-13 2002-11-26 Transkaryotic Therapies Inc Therapy for alpha-galactosidase A deficiency
JP4436934B2 (ja) * 1996-09-13 2010-03-24 ノボザイムス，インコーポレイティド 変更された量のポリペプチドを生成するｄｎａ挿入突然変異を有する細胞
EA199900355A1 (ru) 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
US7332338B2 (en) 1996-10-04 2008-02-19 Lexicon Pharmaceuticals, Inc. Vectors for making genomic modifications
US6855545B1 (en) 1996-10-04 2005-02-15 Lexicon Genetics Inc. Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US6136566A (en) * 1996-10-04 2000-10-24 Lexicon Graphics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
US20040072243A1 (en) * 1996-10-11 2004-04-15 Lexicon Genetics Incorporated Indexed library of cells containing genomic modifications and methods of making and utilizing the same
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
EP0948531A1 (en) * 1996-12-11 1999-10-13 Chiron Corporation Secreted human proteins
US20020168718A1 (en) * 1997-04-03 2002-11-14 California Institute Of Technology Enzyme-mediated modification of fibrin for tissue engineering
WO1998051803A1 (en) 1997-05-16 1998-11-19 Novo Nordisk Biotech, Inc. Polypeptides having prolyl pipeptidyl aminopeptidase activity and nucleic acids encoding same
US7378506B2 (en) * 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6639050B1 (en) * 1997-07-21 2003-10-28 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
KR100622203B1 (ko) * 1997-07-23 2006-09-07 로셰 디아그노스틱스 게엠베하 내인성 유전자 활성화에 의해 사람 단백질을 생성시키는 사람 세포주를 확인하는 방법
WO1999005264A2 (de) * 1997-07-23 1999-02-04 Roche Diagnostics Gmbh Herstellung humaner mutierter proteine in humanen zellen mittels homologer rekombination
ES2273434T3 (es) * 1997-07-23 2007-05-01 Roche Diagnostics Gmbh Obtencion de la eritropoyetina mediante activacion genica endogena.
BR9811542A (pt) * 1997-07-23 2000-08-22 Roche Diagnostics Gmbh Identificação de linhas de células humanas para a produção de proteìnas humanas mediante ativação de genes endógena
US6391633B1 (en) 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
AU776280B2 (en) * 1997-07-23 2004-09-02 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US7316923B1 (en) 1997-09-26 2008-01-08 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
DE69841723D1 (de) * 1997-09-26 2010-07-29 Abt Holding Co Expression von endogenen genen durch homologe rekombination eines vektorkonstruktes mit zellulärer dna
US6897066B1 (en) 1997-09-26 2005-05-24 Athersys, Inc. Compositions and methods for non-targeted activation of endogenous genes
ZA989497B (en) * 1997-10-20 2000-04-19 Roche Diagnostics Gmbh Positive-negative selection in homologous recombination.
EP1992633A1 (en) 1997-11-03 2008-11-19 Human Genome Sciences, Inc. VEGI, an inhibitor of angiogenesis and tumor growth
AU744086B2 (en) * 1997-12-03 2002-02-14 Roche Diagnostics Gmbh Erythropoietin with high specific activity
US7019114B2 (en) 1998-02-19 2006-03-28 Eastern Virginia Medical School Recombinant, biologically active human zona pellucida protein 3 (HZP3) to test male fertility
US7037663B2 (en) * 1998-02-19 2006-05-02 Eastern Virginia Medical School Human zona pellucida protein 3 and uses thereof
WO1999044625A1 (en) 1998-03-03 1999-09-10 John Hopkins University Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
ATE490980T1 (de) 1998-03-19 2010-12-15 Human Genome Sciences Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US6436707B1 (en) * 1998-03-27 2002-08-20 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
US6808921B1 (en) * 1998-03-27 2004-10-26 Lexicon Genetics Incorporated Vectors for gene mutagenesis and gene discovery
JP2002513580A (ja) * 1998-05-07 2002-05-14 トランスカリョティック セラピーズ インコーポレーテッド タンパク質を産生および送達するためのＩＦＮ−α２遺伝子コード領域の上流のゲノム配列
US6242218B1 (en) 1998-05-07 2001-06-05 Transkaryotic Therapies Inc. Genomic sequences for protein production and delivery
NZ507459A (en) * 1998-05-07 2004-01-30 Transkaryotic Therapies Inc Modifying the expression of the fsh beta gene by homologous recombination
EP1080210A2 (en) * 1998-05-27 2001-03-07 Novo Nordisk Biotech, Inc. Methods for producing a polypeptide by modifying the copy number of a gene
WO2000005393A2 (en) 1998-07-21 2000-02-03 Cobra Therapeutics Limited A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
US6894022B1 (en) 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7601685B2 (en) * 1998-08-27 2009-10-13 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US7241730B2 (en) 1998-08-27 2007-07-10 Universitat Zurich Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
SE9803099D0 (sv) 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
US6416975B1 (en) 1998-11-12 2002-07-09 Gliatech, Inc. Human glycine transporter type 2
DE69939330D1 (de) 1998-12-07 2008-09-25 Zymogenetics Inc Wachstumsfaktor-homologe zvegf-3
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
DK1141331T3 (da) 1998-12-16 2009-01-05 Novartis Vaccines & Diagnostic Human cyclinafhængig kinase (hPNQALRE)
JP2004501601A (ja) * 1999-02-19 2004-01-22 アサーシス，インコーポレイテッド 標的化によらない内在性遺伝子の活性化組成物および活性化方法
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
AU3731400A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
AU3864000A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
US6849605B1 (en) * 1999-03-05 2005-02-01 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
WO2000051623A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
UA84387C2 (ru) 1999-03-09 2008-10-27 Займодженетикс, Инк. Человеческий цитокин как лиганд зальфа рецептора и его применение
EP1194572A2 (en) 1999-03-22 2002-04-10 Novozymes Biotech, Inc. Promoter sequences derived from fusarium venenatum and uses thereof
AU779869B2 (en) 1999-04-13 2005-02-17 Nektar Therapeutics Pulmonary administration of dry powder formulations for treating infertility
HK1048650A1 (zh) * 1999-06-15 2003-04-11 Genetrol Biotherapeutics 在细胞培养物中增强细胞激动素(cytokines)的方法
DE60034564T2 (de) 1999-07-07 2007-12-27 Zymogenetics, Inc., Seattle Menschlicher cytokinrezeptor
EP2275559A3 (en) 1999-09-28 2011-03-23 Shire Human Genetic Therapies, Inc. Optimized messenger RNA
AU783767B2 (en) 1999-10-14 2005-12-01 Takara Bio Usa, Inc. Anthozoa derived chromophores/fluorophores and methods for using the same
HK1048828A1 (zh) * 1999-11-19 2003-04-17 Transkaryotic Therapies, Inc. 可令生产优化的核酸构造
EP1232175B1 (en) 1999-11-22 2009-07-08 ZymoGenetics, Inc. Method of forming a peptide-receptor complex with zsig33 polypeptides.
US8168178B2 (en) 1999-11-30 2012-05-01 Curis, Inc. Methods and compositions for regulating lymphocyte activity
US6951839B1 (en) 1999-11-30 2005-10-04 Curis, Inc. Methods and compositions for regulating lymphocyte activity
WO2001042442A2 (en) 1999-12-10 2001-06-14 Cytos Biotechnology Ag Activation of endogenous genes by genomic introduction of a replicon
EP2194130A1 (en) 1999-12-23 2010-06-09 ZymoGenetics, L.L.C. Cytokine ZCYTO18
EP1985701B1 (en) 2000-01-10 2012-05-30 Novartis Vaccines and Diagnostics, Inc. Genes differentially expressed in breast cancer
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
EP1728862A1 (en) 2000-03-16 2006-12-06 Genetica, Inc. Methods and compositions for RNA interference
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20020077775A1 (en) * 2000-05-25 2002-06-20 Schork Nicholas J. Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
US20030195707A1 (en) * 2000-05-25 2003-10-16 Schork Nicholas J Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
EP1294949A4 (en) 2000-06-15 2004-08-25 Human Genome Sciences Inc HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
GB0018876D0 (en) * 2000-08-01 2000-09-20 Applied Research Systems Method of producing polypeptides
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
DE60143959D1 (de) 2000-08-25 2011-03-10 Basf Plant Science Gmbh En kodieren
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
EP1318834A2 (en) * 2000-09-12 2003-06-18 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US7381713B2 (en) * 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
AU2002236569A1 (en) * 2000-12-04 2002-06-18 Sloan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
AU3323002A (en) * 2000-12-20 2002-07-01 Hoffmann La Roche Erythropoietin conjugates
EP1345628B1 (en) 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
TW201022287A (en) 2001-01-03 2010-06-16 Senomyx Inc T1R taste receptors and genes encoding same
WO2002059337A1 (en) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof
WO2002064612A2 (en) 2001-02-09 2002-08-22 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
AU2002257067A1 (en) 2001-03-14 2002-09-24 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
WO2002081641A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
WO2002081640A2 (en) * 2001-04-06 2002-10-17 Georgetown University Gene shinc-1 and diagnostic and therapeutic uses thereof
WO2002081642A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
AU2002342613A1 (en) * 2001-05-09 2002-11-25 Geron Corporation Treatment for wounds
US7309783B2 (en) * 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
EP1412750B1 (en) 2001-06-26 2012-05-23 Senomyx, Inc. T1r2-t1r3 hetero-oligomeric sweet taste receptors and cell lines that express said receptors and use thereof for identification of sweet taste compounds
IL159640A0 (en) 2001-07-10 2004-06-01 Senomyx Inc Use of specific t2r taste receptors to identify compounds that block bitter taste
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
WO2003011118A2 (en) * 2001-08-02 2003-02-13 Trinity Biomedical Technology Corporation Human zona pellucida proteins and methods of their use in diagnosing male infertility
WO2003014151A2 (en) * 2001-08-10 2003-02-20 Genset S.A. Human secreted proteins, their encoding polynucleotides, and uses thereof
US20050064587A1 (en) * 2001-09-07 2005-03-24 Lawrence Rosenberg Pancreatic small cells and uses thereof
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
WO2003046180A2 (en) * 2001-11-28 2003-06-05 Genset S.A. Human cdnas and proteins and uses thereof
US7247609B2 (en) * 2001-12-18 2007-07-24 Universitat Zurich Growth factor modified protein matrices for tissue engineering
WO2003054158A2 (en) * 2001-12-19 2003-07-03 The University Of Chicago Rapidly maturing fluorescent proteins and methods for using the same
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
RU2490276C2 (ru) 2002-01-18 2013-08-20 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
US20060122374A1 (en) 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides
CA2476894A1 (en) 2002-02-20 2003-08-28 American Integrated Biologics, Inc. Transgenic production in saliva
US20100151556A1 (en) * 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (en) * 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US8206965B2 (en) * 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
US7138512B2 (en) * 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) * 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
EP1499739B1 (en) 2002-04-22 2016-03-30 Novozymes, Inc. Methods for increasing homologous recombination of a nucleic acid sequence
DK1503788T3 (da) 2002-04-25 2011-10-17 Shire Human Genetic Therapies Behandling af alpha-galactosidase A-deficiens
US20030228317A1 (en) * 2002-05-22 2003-12-11 Prafulla Gokhale Gene BRCC-1 and diagnostic and therapeutic uses thereof
WO2004009775A2 (en) 2002-07-19 2004-01-29 Targacept, Inc. Methods and compositions relating to chimeric nicotinic receptor subunits
US7459435B2 (en) * 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
ATE542913T1 (de) 2002-11-18 2012-02-15 Novozymes Inc Promotorvarianten zur expression von genen in einer pilzzelle
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
MXPA05005398A (es) * 2002-11-22 2006-03-09 Univ Johns Hopkins Meta para terapia de deterioro cognitivo.
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
US20060100131A1 (en) * 2002-12-10 2006-05-11 Lynn Megeney Modulation of stem cell differentiation by modulation of caspase-3 activity
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
CA2802143C (en) 2003-01-14 2018-06-19 Dana-Farber Cancer Institute Sparc encoding polynucleotide as a cancer therapy sensitizer
AU2004206250B8 (en) * 2003-01-21 2009-09-17 Bristol-Myers Squibb Company Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
CN110496230A (zh) 2003-02-11 2019-11-26 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
WO2004098634A2 (en) * 2003-04-30 2004-11-18 Government Of The United States Of America As Represented By The Sercretary Of The Department Of Health And Human Services National Institutes Of Health Protein arginine n-methyltransferase 2 (prmt-2)
US20060252120A1 (en) * 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
JP2007500016A (ja) * 2003-06-11 2007-01-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド 培養においてタンパク質生成を増大させるための方法
EP1659881B1 (en) 2003-08-06 2019-04-03 Senomyx Inc. Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US11311574B2 (en) 2003-08-08 2022-04-26 Sangamo Therapeutics, Inc. Methods and compositions for targeted cleavage and recombination
CN1860232A (zh) * 2003-09-30 2006-11-08 莱克康遗传公司 鉴别基因功能的方法和组合物
WO2005046746A2 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
WO2005052140A2 (en) 2003-11-20 2005-06-09 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multipotent postnatal stem cells from human periodontal ligament and uses thereof
CN1938333A (zh) * 2003-12-03 2007-03-28 达尔塔生物技术有限公司 白介素－11融合蛋白
PL1696947T3 (pl) * 2003-12-19 2014-08-29 Hoffmann La Roche Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelit
MXPA06008126A (es) * 2004-01-14 2008-02-14 Univ Ohio Metodos para la produccion de peptidos/proteinas en plantas y peptidos/proteinas producidos de este modo.
EP1732944B1 (en) 2004-04-07 2012-09-05 The University of Chicago Monomeric red fluorescent proteins
EP1751177A4 (en) 2004-04-19 2008-07-16 Univ Ohio CROSSLINKABLE GLYCOPROTEINS AND METHODS OF MAKING THE SAME
EP1774031A2 (en) * 2004-05-26 2007-04-18 Wisconsin Alumni Research Foundation Cancer treatment method by inhibiting mage gene expression or function
EP1789070B1 (en) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in neuronal function
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
AU2005318097A1 (en) * 2004-12-22 2006-06-29 Kuros Biosurgery Ag Michael-type addition reaction functionalised peg hydrogels with factor XIIIA incorporated biofactors
KR20070082597A (ko) 2004-12-30 2007-08-21 에이전시 포 사이언스, 테크놀로지 앤드 리서치 유전자
US8575101B2 (en) 2005-01-06 2013-11-05 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
WO2006073711A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Use of a matrix comprising a contrast agent in soft tissues
WO2006072622A2 (en) * 2005-01-06 2006-07-13 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
EP1859028B1 (en) 2005-02-10 2015-12-02 Regents Of The University Of Minnesota Vascular endothelial cells
US20060194740A1 (en) * 2005-02-25 2006-08-31 Ulevitch Richard J NOD1 as an anti-tumor agent
US20060234973A1 (en) * 2005-04-14 2006-10-19 Kevin Fitzgerald Transcription factor RNA interference reagents and methods of use thereof
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US20070011752A1 (en) * 2005-05-06 2007-01-11 American Integrated Biologics, Inc. Production of human proteins in transgenic animal saliva
EP3683230A1 (en) 2005-05-12 2020-07-22 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
EP1904652A2 (en) * 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
US20080242834A1 (en) * 2005-07-08 2008-10-02 Ohio University Methods of Predicting Hyp-Glycosylation Sites For Proteins Expressed and Secreted in Plant Cells, and Related Methods and Products
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
EP3031470A3 (en) 2005-09-09 2016-08-10 The Johns Hopkins University Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
US20070072795A1 (en) * 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
JP5342878B2 (ja) 2005-10-20 2013-11-13 セノミクス・インコーポレーテッド キメラヒト甘味‐旨味および旨味‐甘味味覚受容体
WO2007060495A1 (en) * 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007053732A2 (en) 2005-11-01 2007-05-10 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the blys gene and use in diagnostic methods
RU2008115455A (ru) 2005-11-03 2009-12-10 Рэдпойнт Био Корпорэйшн (Us) Высокопроизводительный скрининг-анализ ионного канала trpm5
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
ES2391657T3 (es) 2006-02-07 2012-11-28 Shire Human Genetic Therapies, Inc. Composiciones estabilizadas de proteínas que tienen un resto tiol libre
US9109204B2 (en) * 2006-02-28 2015-08-18 The Trustees Of Columbia University In The City Of New York Methods for compact aggregation of dermal cells
TWI428448B (zh) * 2006-03-24 2014-03-01 Syntonix Pharmaceuticals Inc 作為第九因子（ｆａｃｔｏｒ ｉｘ）原肽處理酶之ｐｃ５
DK3235811T3 (en) 2006-04-21 2018-11-12 Senomyx Inc PROCEDURE FOR THE PREPARATION OF OXALAMIDS
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2008013861A2 (en) 2006-07-27 2008-01-31 Redpoint Bio Corporation Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
CN101534847A (zh) 2006-08-04 2009-09-16 普罗龙药品公司 修饰型促红细胞生成素
WO2008019368A2 (en) * 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
EP2136778A2 (en) * 2007-03-20 2009-12-30 Harold Brem Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
EP2139447A2 (en) * 2007-03-20 2010-01-06 Harold Brem Gm-csf cosmeceutical compositions and methods of use thereof
WO2008125655A1 (en) * 2007-04-13 2008-10-23 Kuros Biosurgery Ag Polymeric tissue sealant
AU2008240080A1 (en) 2007-04-16 2008-10-23 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
AR067537A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
EP2182943B1 (en) 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
HUE025137T2 (en) 2007-08-21 2016-01-28 Senomyx Inc Compositions are bitter taste blocking (blocking) compounds
US8679749B2 (en) * 2007-11-01 2014-03-25 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
US8003325B2 (en) * 2007-11-30 2011-08-23 Mayo Foundation For Medical Education And Research Polymorphisms of the BLyS gene and use in diagnostic methods
EP2227263A2 (en) * 2007-12-28 2010-09-15 Kuros Biosurgery AG Pdgf fusion proteins incorporated into fibrin foams
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
WO2009137613A2 (en) 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
EP3488837B1 (en) 2009-07-15 2024-11-27 NewSouth Innovations Pty Limited Electroporation apparatus for providing agents to the cochlea
AU2010281403B2 (en) 2009-07-28 2016-03-10 Takeda Pharmaceutical Company Limited Compositions and methods for treating Gaucher disease
CA2773133A1 (en) 2009-08-28 2011-03-03 Edward H. Schuchman Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
EP2525808A2 (en) 2010-01-19 2012-11-28 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
PL2552961T3 (pl) 2010-03-30 2018-04-30 Janssen Biotech, Inc. Humanizowane przeciwciała il-25
ES2500048T3 (es) 2010-09-14 2014-09-29 F. Hoffmann-La Roche Ag Procedimiento para purificar eritropoyetina pegilada
PT2635299T (pt) 2010-11-02 2019-10-14 Univ Columbia Métodos de tratamento de distúrbios de perda de cabelo
DK2646558T3 (en) 2010-11-30 2016-10-03 Novozymes Inc Promoters for expression of genes in a fungal cell
WO2012075412A1 (en) 2010-12-03 2012-06-07 Michael Verneris Generation of natural killer cells and lymphoid tissue inducer-like (lti-like) nk-22 cells
AU2011338504B2 (en) 2010-12-07 2015-01-22 Vnomics Corp. System and method for measuring and reducing vehicle fuel waste
WO2012083081A1 (en) 2010-12-16 2012-06-21 Novozymes, Inc. Promoters for expressing genes in a fungal cell
WO2012092374A2 (en) 2010-12-31 2012-07-05 Short Jay M Express humanization of antibodies
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
ES2882852T3 (es) 2011-03-16 2021-12-02 Kuros Biosurgery Ag Formulación farmacéutica para la utilización en la fusión espinal
RU2495933C2 (ru) * 2011-05-30 2013-10-20 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ПЛАЗМИДА ДЛЯ ЭКСПРЕССИИ В КЛЕТКАХ БАКТЕРИИ РОДА Escherichia ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТКАНЕВОГО АКТИВАТОРА ПЛАЗМИНОГЕНА (ТАП) ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), БАКТЕРИЯ, ПРИНАДЛЕЖАЩАЯ К РОДУ Escherichia, - ПРОДУЦЕНТ ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ) ИЛИ [-1]МЕТИОНИЛ-ФРАГМЕНТ ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), ПРЕДШЕСТВЕННИК РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ), СПОСОБ ПОЛУЧЕНИЯ ПРЕДШЕСТВЕННИКА РЕКОМБИНАНТНОГО ФРАГМЕНТА ТАП ЧЕЛОВЕКА (РЕТЕПЛАЗЫ)
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
WO2013130963A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
WO2013177287A1 (en) * 2012-05-22 2013-11-28 Georgia Regents University Methods and vectors for gene targeting with inducible specific expression
IN2015DN01115A (cs) 2012-07-13 2015-06-26 Zymeworks Inc
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
CN103864913A (zh) 2012-12-18 2014-06-18 联亚生技开发股份有限公司 重组蛋白
EP2851086A1 (en) 2013-09-20 2015-03-25 Sanofi Serpins: methods of therapeutic ß-cell regeneration and function
EP2769732A1 (en) 2013-02-22 2014-08-27 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
WO2014128257A1 (en) 2013-02-22 2014-08-28 Sanofi Serpins: methods of therapeutic beta-cell regeneration and function
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
US10066001B2 (en) 2013-03-15 2018-09-04 Apotex Inc. Enhanced liquid formulation stability of erythropoietin alpha through purification processing
US10239951B2 (en) 2013-05-08 2019-03-26 Zymeworks Inc. Bispecific HER2 and HER3 antigen binding constructs
EP3010582B1 (en) 2013-06-21 2021-04-28 Newsouth Innovations Pty Limited Method and apparatus for close-field electroporation
US11306328B2 (en) * 2013-07-26 2022-04-19 President And Fellows Of Harvard College Genome engineering
WO2016081728A1 (en) 2014-11-19 2016-05-26 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for frailty associated with aging
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
US9650441B2 (en) 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
SI3370733T1 (sl) 2015-11-02 2021-11-30 Board Of Regents The University Of Texas System Postopek za aktivacijo CD40 in blokada imunske nadzorne točke
EP3436477A2 (en) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
WO2018014039A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
WO2018011381A1 (en) 2016-07-15 2018-01-18 F. Hoffmann-La Roche Ag Method for purifying pegylated erythropoietin
BR112019000683A2 (pt) 2016-07-15 2019-04-24 Poseida Therapeutics Inc receptores de antígeno quiméricos e métodos para uso
CN110199015A (zh) 2016-09-30 2019-09-03 波赛达治疗公司 修饰干细胞记忆t细胞、其制造方法与使用方法
EP3519049B1 (en) 2016-09-30 2025-12-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-il23 specific antibody
US20190119636A1 (en) 2017-10-23 2019-04-25 Poseida Therapeutics, Inc. Modified stem cell memory t cells, methods of making and methods of using same
WO2018068022A1 (en) 2016-10-06 2018-04-12 Poseida Therapeutics, Inc. Inducible caspases and methods for use
JP7645607B2 (ja) 2016-11-16 2025-03-14 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で乾癬を治療する方法
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
KR102708285B1 (ko) 2017-03-13 2024-09-20 포세이다 테라퓨틱스, 인크. 조혈 줄기세포의 선택적 제거 및 대체를 위한 조성물 및 방법
JP2020532987A (ja) 2017-09-08 2020-11-19 ポセイダ セラピューティクス，インコーポレイティド キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US10329543B2 (en) 2017-10-23 2019-06-25 Poseida Therapeutics, Inc. Modified stem cell memory T cells, methods of making and methods of using same
MX2020004716A (es) 2017-11-06 2020-11-06 Janssen Biotech Inc Método seguro y eficaz para tratar la artritis psoriásica con el anticuerpo específico anti-il23.
AR113862A1 (es) 2017-12-01 2020-06-17 Seattle Genetics Inc Anticuerpos anti-cd47 y sus usos para tratar cáncer
AU2018393110B2 (en) 2017-12-20 2023-04-27 Poseida Therapeutics, Inc. VCAR compositions and methods for use
PL3731873T3 (pl) 2017-12-29 2022-04-25 F. Hoffmann-La Roche Ag Sposób dostarczania kompozycji pegylowanego białka
US12208142B2 (en) 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
CN111801120A (zh) 2017-12-29 2020-10-20 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
JP7516250B2 (ja) 2018-03-05 2024-07-16 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
BR112020018049A2 (pt) 2018-03-07 2020-12-29 Poseida Therapeutics, Inc. Composições de cartirina e métodos para uso
SI3781943T1 (sl) 2018-04-20 2022-07-29 Janssen Biotech, Inc. Kvalifikacija kromatografske kolone v proizvodnih postopkih za proizvodnjo sestavkov protitelesa proti IL12/IL23
WO2020016838A2 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained response predictors after treatment with anti-il23 specific antibody
CA3111384A1 (en) 2018-09-05 2020-03-12 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
WO2020128864A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
EP3898993A1 (en) 2018-12-20 2021-10-27 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
US20220153827A1 (en) 2019-01-15 2022-05-19 Janssen Biotech, Inc. Anti-TNF Antibody Compositions and Methods for the Treatment of Juvenile Idiopathic Arthritis
KR20210118878A (ko) 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
EP3938390A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
KR20210141990A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-il12/il23 항체 조성물을 생성하기 위한 제조 방법
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
MX2021011328A (es) 2019-03-18 2021-12-10 Janssen Biotech Inc Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23.
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
JP2022536279A (ja) 2019-06-03 2022-08-15 ヤンセン バイオテツク，インコーポレーテツド 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
MA56026A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
US20200385453A1 (en) 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
TW202112354A (zh) 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 遮蔽抗體調配物
TW202112801A (zh) 2019-06-05 2021-04-01 美商西雅圖遺傳學公司 純化遮蔽抗體之方法
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
MX2022002337A (es) 2019-08-27 2022-06-08 Tonix Pharma Ltd Polipéptidos de tff2 modificados.
WO2021046261A1 (en) 2019-09-05 2021-03-11 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CN115135672A (zh) 2019-12-20 2022-09-30 波赛达治疗公司 抗muc1组合物和使用方法
CN115515646A (zh) 2020-03-04 2022-12-23 波赛达治疗公司 用于治疗代谢性肝病的组合物和方法
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
US20230190811A1 (en) 2020-04-14 2023-06-22 Poseida Therapeutics, Inc. Compositions and methods for use in the treatment of cancer
CA3181949A1 (en) 2020-05-05 2021-11-11 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
AU2021308574A1 (en) 2020-07-13 2023-03-09 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
WO2022024065A1 (en) 2020-07-30 2022-02-03 Janssen Biotech, Inc. Method of treating psoriasis in pediatric subjects with anti-il12/il23 antibody
WO2022087148A1 (en) 2020-10-21 2022-04-28 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
EP4298205A1 (en) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
WO2022182792A1 (en) 2021-02-23 2022-09-01 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
EP4301863A1 (en) 2021-03-04 2024-01-10 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
BR112023018353A2 (pt) 2021-03-12 2024-02-06 Janssen Biotech Inc Método seguro e eficaz para tratamento da artrite psoriática com anticorpo específico anti-il23
IL309997A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
US20230038355A1 (en) 2021-07-09 2023-02-09 Janssen Biotech, Inc. Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
US20240352080A1 (en) 2021-07-14 2024-10-24 Seagen Inc. Antibody Masking Domains
WO2023049825A1 (en) 2021-09-24 2023-03-30 Seagen Inc. Improved antibody masking domains
WO2023060089A2 (en) 2021-10-04 2023-04-13 Poseida Therapeutics, Inc. Transposases and uses thereof
AU2022360244A1 (en) 2021-10-04 2024-04-11 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
KR20240099352A (ko) 2021-10-29 2024-06-28 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
JP2024544555A (ja) 2021-11-15 2024-12-03 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体によるクローン病を処置する方法
KR20240103043A (ko) 2021-11-23 2024-07-03 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 궤양성 결장염을 치료하는 방법
EP4465962A1 (en) 2022-01-21 2024-11-27 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
WO2023164573A1 (en) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
EP4526342A1 (en) 2022-05-18 2025-03-26 Janssen Biotech, Inc. Method for evaluating and treating psoriatic arthritis with il23 antibody
JP2025528163A (ja) 2022-08-11 2025-08-26 ポセイダ セラピューティクス，インコーポレイティド キメラｃｄ８－アルファ補助受容体組成物及び使用方法
US20260151538A1 (en) 2022-10-26 2026-06-04 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
AU2023383916A1 (en) 2022-11-22 2025-07-10 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024129459A1 (en) 2022-12-16 2024-06-20 University Of Rochester Repairmen! of barrier dysfunction in esophagus
CN121079405A (zh) 2023-02-21 2025-12-05 波西达治疗公司 用于基因组编辑的组合物和方法
KR20250155027A (ko) 2023-02-21 2025-10-29 포세이다 테라퓨틱스, 인크. Aav piggybac 트랜스포존 폴리뉴클레오티드 조성물 및 이의 사용 방법
AU2024226443A1 (en) 2023-02-21 2025-08-28 Demeetra Agbio, Inc. Compositions and methods for genome editing
WO2024211512A2 (en) 2023-04-05 2024-10-10 Poseida Therapeutics, Inc. Transposases and uses thereof
KR20250173518A (ko) 2023-04-05 2025-12-10 포세이다 테라퓨틱스, 인크. 트랜스포사제 폴리뉴클레오티드 및 그의 용도
CN121195063A (zh) 2023-04-05 2025-12-23 波西达治疗公司 嵌合转座酶及其用途
KR20260010721A (ko) 2023-05-10 2026-01-21 포세이다 테라퓨틱스, 인크. 트랜스포사제 및 이의 용도
IL327036A (en) 2023-09-19 2026-05-01 Poseida Therapeutics Inc Compositions and methods for combining viral vectors
WO2025160432A1 (en) 2024-01-26 2025-07-31 Poseida Therapeutics, Inc. Methods and compositions for enhancing in vivo persistence and potency of cell therapy
CA3249015A1 (en) 2024-03-20 2025-10-31 Janssen Biotech, Inc. Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025259466A1 (en) 2024-06-13 2025-12-18 University Of Rochester Gm-csf and gm-csf-induced dendritic cells enhance fracture healing and bone repair
WO2025262604A1 (en) 2024-06-17 2025-12-26 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
CA3258952A1 (en) 2024-06-27 2026-03-01 Janssen Biotech, Inc. Methods of treating ulcerative colitis with anti-il23 specific antibody
WO2026064550A1 (en) 2024-09-19 2026-03-26 Poseida Therapeutics, Inc. Transposases and uses thereof
WO2026080393A1 (en) 2024-10-07 2026-04-16 Poseida Therapeutics, Inc. Compositions and methods for use in car cell therapies
WO2026107088A1 (en) 2024-11-13 2026-05-21 Poseida Therapeutics, Inc. Dual car constructs and methods of use
WO2026107078A1 (en) 2024-11-13 2026-05-21 Poseida Therapeutics, Inc. Chimeric antigen receptor compositions and methods of use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656134A (en) * 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
IE56716B1 (en) * 1983-01-19 1991-11-20 Genentech Inc Method for producing human tpa and expression vectors therefor
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US4822736A (en) * 1984-07-05 1989-04-18 Baylor College Of Medicine Amplification of adenosine deaminase genes in mammalian cells using adenosine, alanosine, uridine, and deoxycoformycin
DE3681787D1 (de) * 1985-07-05 1991-11-07 Whitehead Biomedical Inst Expression von fremdem genetischem material in epithelzellen.
EP0236059B1 (en) * 1986-02-27 1994-04-27 Snow Brand Milk Products Co. Ltd. Preparation of erythropoietin-producing cells and production process of erythropoietin using same
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
GB8615942D0 (en) * 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
ATE145558T1 (de) * 1987-05-01 1996-12-15 Gen Hospital Corp Transkaryotische einpflanzung
GB8718779D0 (en) * 1987-08-07 1987-09-16 Grosveld F G Dna sequence & expression vector
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5043270A (en) * 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
EP0478696B1 (en) * 1989-06-23 1995-04-12 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE Efficient method for identifiable expression of non-selectable genes
SG88714A1 (en) * 1989-11-06 2002-05-21 Cell Genesys Inc Production of proteins using homologous recombination
DE779362T1 (de) * 1989-12-22 2001-04-05 Applied Research Systems Ars Holding N.V., Curacao DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
HUT60523A (en) * 1990-02-22 1992-09-28 Biogen Inc Improved process for expressing polypeptides
IT1241123B (it) * 1990-04-19 1993-12-29 Consiglio Nazionale Ricerche Cellule umane per l'elevata espressione di geni inseriti in dna ricombinanti episomiali,loro preparazione e loro impiego
EP0535144A4 (en) * 1990-06-12 1993-08-11 Baylor College Of Medicine Method for homologous recombination in animal and plant cells
CA2090473A1 (en) * 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
ATE159548T1 (de) * 1990-11-13 1997-11-15 Immunex Corp Bifunktionelle wählbare fusionsgene
ATE177784T1 (de) * 1990-12-07 1999-04-15 Univ Florida Rekombinante zellen, die stark chromosomal- integrierte heterologe gene exprimieren
SG93780A1 (en) * 1991-05-06 2003-01-21 Cell Genesys Inc Gene manipulation and expression using genomic elements
AU664847B2 (en) * 1991-05-15 1995-12-07 Cell Genesys, Inc. Genomic modifications with homologous DNA targeting
WO1993004169A1 (en) * 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
MX9305183A (es) * 1992-08-27 1994-05-31 Us Agriculture Intron portatil, molecula de adn genomico viral, virus vivo y vacuna que los contiene y metodo para su obtencion.
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery

Also Published As

Publication number Publication date
ZA953879B (en) 1996-01-18
IL113708A0 (en) 1995-08-31
KR970703429A (ko) 1997-07-03
NZ285945A (en) 1998-03-25
WO1995031560A1 (en) 1995-11-23
KR100379356B1 (ko) 2003-06-09
HU9603144D0 (en) 1997-01-28
UA34493C2 (uk) 2001-03-15
JPH10500570A (ja) 1998-01-20
CA2190289A1 (en) 1995-11-23
CZ295115B6 (cs) 2005-05-18
EP0759082A1 (en) 1997-02-26
FI964536L (fi) 1997-01-09
BR9507874A (pt) 1997-08-19
MX9605542A (es) 1998-05-31
NO964802D0 (no) 1996-11-12
US5641670A (en) 1997-06-24
AU709058B2 (en) 1999-08-19
FI964536A7 (fi) 1997-01-09
AU2550495A (en) 1995-12-05
RU2267533C2 (ru) 2006-01-10
FI964536A0 (fi) 1996-11-12
SK146196A3 (en) 1998-02-04
CZ325896A3 (en) 1997-12-17
HUT76844A (en) 1997-11-28

Similar Documents

Publication Publication Date Title
NO964802D0 (no) DNA konstruksjoner for effektiv homolog rekombinasjon og anvendelser derav
FI971176A7 (fi) DNA-fotopilkkominen käyttäen teksapyriinejä
DE69822614D1 (de) Dna kapillare
DE69632451D1 (de) Zange
DE69632491D1 (de) Ausnehmer
DE69423747D1 (de) Elektrisches heizgerät
NO964628D0 (no) DNA-sekvenser
FI962980L (fi) Muunnetut oligonukleotidit
DE69526758D1 (de) Sortiersystem
HUT77108A (hu) DNS-szekvenciák és alkalmazásuk
DE69532874D1 (de) RPDL Protein und kodierende DNS
NO963474D0 (no) Oppvarmingssystem
DE59505759D1 (de) Binderrücken
DE69715753D1 (de) Heizgerät
DE69532881D1 (de) Ecdn - protein und dafuer kodeierende dna
ATA77694A (de) Heizungsanlage
DE69724736D1 (de) Prozessablaufsteuerung
ATA101796A (de) Heizgerät
NO961131D0 (no) Elektrisk varmeovn
KR970053219U (ko) 화분화환
KR950032371U (ko) 가열용 지지대
DE69519715D1 (de) PRLTS-Proteine und die dafür kodierende DNA
GB2335193B (en) Rainbow trout ILβ; encoding nucleic acid; materials and methods
KR980000165U (ko) 전기 훈증기용 히터
FI951693A0 (fi) Centralt dammsugarsystem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application